American Society of Hematology

Figure 3

$Figure 3. Human hematopoietic engraftment potential in NOD/SCID mice is restricted to CD34+ UCB cells expressing BB9. (A) Sort regions used for isolation of CD34+BB9+ () and CD34+BB9− (◆) cells. (B and C) Representative examples displaying flow cytometric analysis of bone marrow from NOD/SCID recipients of CD34+BB9− and CD34+BB9+ UCB, respectively. Human (Hu45) and murine (Mu45) hematopoietic cells are identified by species-specific anti-CD45 immunolabeling. (D) Proportion of human CD45+ cells in individual animals that received a transplant of 2 × 106 unfractionated mononuclear cells (MNCs), and between 1 to 2 × 105 CD34+BB9− or CD34+BB9+ cells. — represents the median percentage of human CD45+ cells of each group. (E) Representative example of multilineage human hematopoietic engraftment in an animal that received a transplant of 1× 105 CD34+BB9+ cells. Both myeloid (CD11b, CD14, CD15) and B-lymphoid (CD19, CD20) progeny are evident.$

Human hematopoietic engraftment potential in NOD/SCID mice is restricted to CD34⁺ UCB cells expressing BB9. (A) Sort regions used for isolation of CD34⁺BB9⁺ () and CD34⁺BB9⁻ (◆) cells. (B and C) Representative examples displaying flow cytometric analysis of bone marrow from NOD/SCID recipients of CD34⁺BB9⁻ and CD34⁺BB9⁺ UCB, respectively. Human (Hu45) and murine (Mu45) hematopoietic cells are identified by species-specific anti-CD45 immunolabeling. (D) Proportion of human CD45⁺ cells in individual animals that received a transplant of 2 × 10⁶ unfractionated mononuclear cells (MNCs), and between 1 to 2 × 10⁵ CD34⁺BB9⁻ or CD34⁺BB9⁺ cells. — represents the median percentage of human CD45⁺ cells of each group. (E) Representative example of multilineage human hematopoietic engraftment in an animal that received a transplant of 1× 10⁵ CD34⁺BB9⁺ cells. Both myeloid (CD11b, CD14, CD15) and B-lymphoid (CD19, CD20) progeny are evident.

This Feature Is Available To Subscribers Only